Effects of Allulose and Aspartame Intake on Postprandial Glucagon-Like Peptide-1 Profile and Metabolic Health Indicators

The Sweetener Question Has Two Sides

Sweetener selection used to be a sugar-for-sugar swap. Now formulators want to know how a sweetener behaves after ingestion, not just in the mixing bowl. A new research paper takes that question directly to two very different sweeteners: allulose and aspartame. The main goal is to compare their acute effects on postprandial glucagon-like peptide 1 (GLP-1) profiles in healthy adults. The paper also outlines measurements for gut microbiota, short-chain fatty acids, and insulin sensitivity.

Why GLP-1 Matters

When you eat, gut cells release GLP-1. This hormone stimulates insulin, slows gastric emptying, and signals satiety. Foods and sweeteners that change GLP-1 can change how a product affects appetite and glucose response. That’s why this trial compares allulose against aspartame.

Many sugar substitutes deliver sweetness, but they do not deliver the same metabolic signals. Allulose is not a high-intensity sweetener. It is a bulk sweetener with about 0.2–0.4 kcal/g. It browns, contributes texture, and fills volume in a formulation. Those properties make it functionally closer to sugar. Aspartame sits in a completely different category. The study design recognizes that difference rather than ignoring it.

What the Study Did

Healthy adults will take a single dose of allulose or aspartame. Researchers will then track the postprandial GLP-1 profile at multiple time points. The word “postprandial” matters here. This is an acute response, not a weeks-long feeding study.

The team will also evaluate gut microbiota composition, short-chain fatty acids, and insulin sensitivity. Your technical staff will want to see those endpoints. A sweetener can look clean on the label but still change the gut environment. This trial puts that assumption under the microscope.

The paper appears under DOI 10.2196/81857. It gives the research community a clear protocol for comparing two sweeteners that are often treated as interchangeable. They are not.

Key Evidence: What the Trial Will Measure

Measurement	What the team will track	Why formulators should care
Postprandial GLP-1 profile	Difference after allulose vs aspartame intake	GLP-1 relates to insulin release and satiety signaling
Gut microbiota composition	Shifts in microbial populations	Gut health is a major selling point in better-for-you products
Short-chain fatty acids	Fermentation products	A direct read on how the gut processes each sweetener
Insulin sensitivity	Metabolic response beyond GLP-1	Relevant for products aimed at glucose control

No final GLP-1 numbers are available yet. That’s not a weakness. It’s a sign that the study is designed before the hype gets written.

What This Means for Manufacturers

Read the paper for its limits. It states the objective and the planned outcomes, not the results. But the direction is clear. If allulose produces a different GLP-1 response than aspartame, formulators gain a functional reason to use it beyond browning and bulk.

Allulose already earns its place in baked goods, sauces, and frozen desserts because it handles heat and provides body without sugar’s calorie load. The evidence in this paper puts that energy density at 0.2–0.4 kcal/g. Now imagine a product where the sweetener also contributes to the metabolic story. That is the opportunity.

The data just aren’t in yet. But the endpoints tell you what to watch: GLP-1, gut bacteria, short-chain fatty acids, and insulin sensitivity. If any one of those moves in the right direction, allulose suddenly becomes a much stronger candidate for metabolic health claims.

FAQ: Allulose vs Aspartame

Will this study settle the allulose-vs-aspartame debate?
No. This is a trial plan, not a final verdict. The primary objective is to measure postprandial GLP-1 differences. The results will add one important piece of evidence, but a single acute study won’t be the last word.

How should an ingredient buyer use this data now?
Watch the endpoints. If your product is positioned around metabolic health, you need to know how each sweetener affects GLP-1 and gut markers. Use the pending data to pressure-test supplier claims. Ask questions before you commit volume.

Does allulose still need bulking agents?
That depends on the system. In many recipes, allulose provides volume and texture on its own. The paper highlights those functional properties. But formulation always comes down to your specific starch, protein, and moisture profiles.

The Next Steps

Sweetener decisions now run through two lenses: how the ingredient behaves in the product and how it behaves in the body. Allulose sits in a rare position on both fronts. It handles heat, adds texture, and delivers 0.2–0.4 kcal/g. This research adds another layer to that story.

Stay close to the GLP-1 findings as they become public. They may change how you brief your supplier, your R&D team, and your marketing partners. The trial won’t end the debate. But it will give the next one a much sharper starting line.